Clinical trials: CGM
Type 2 Diabetes
A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range)
This study is being done to evaluate glycemic control in participants with type 2 diabetes who are taking mealtime insulin LY900014 in combination with long-acting insulin glargine.
- Trial name
- NCT04605991
- Testing
- LY900014, Insulin Glargine
- Where
- 32 sites in United States, Puerto Rico
- Volunteers
- 187 people
- Sponsor
- Eli Lilly and Company
Diabetes Type 1
InPen User Experience
The purpose of this study is to evaluate the user experience of InPen™ with InPen™ Diabetes Management App and Guardian 4 system in adult patients with type 1 diabetes for the design of a future pivotal study.
- Trial name
- NCT05029271
- Testing
- InPen with Guardian 4 System
- Where
- 3 sites in Sweden
- Volunteers
- 34 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes Mellitus
A Continuous Glucose Monitor Based Insulin Bolus Calculator (CGM-IBC) Study B
This study examines the safety of an app-based insulin bolus calculator that utilizes glucose values from a continuous glucose monitor.
- Trial name
- NCT05343065
- Testing
- BlueStar 10
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Welldoc
Glycemic Control, Diet, Food and Nutrition
Using CGM for Evaluating Effects of Food on Glucose Regulation in Healthy Humans
The specific goal of this pilot study is to evaluate if it is possible to detect a statistical difference in postprandial glycemia after meals served with and without a drink previously shown to reduce postprandial glycemia by…
- Trial name
- NCT04848233
- Where
- Sweden
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- DoubleGood AB
Diabetes Mellitus
Feasibility Study to Evaluate an Intravascular Blood Continuous Glucose Sensor
The goal of this early first in man clinical trial is to evaluate the safety of an implantable continuous blood glucose monitoring system in participants with Diabetes Mellitus.
- Trial name
- NCT06764069
- Testing
- Sensor Lead
- Where
- Brazil
- Volunteers
- 10 people
- Sponsor
- Glucotrack
Diabetes
Observational Study to Evaluate the Effectiveness and Safety Study of the Dexcom G4™ Continuous Glucose Monitoring System
The purpose of this study is to evaluate the effectiveness and safety of the Dexcom G4 System when used as an adjuvant to blood glucose testing.
- Trial name
- NCT01514305
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- DexCom, Inc.
Diabetes, Pre-diabetes
Glucose Risk Assessment in Employer Populations
This is an observational study to understand the glucose characteristics of the general population (normal glucose, pre-diabetes, and diabetes).
- Conditions
- Diabetes, Pre-diabetes, Glucose Intolerance
- Trial name
- NCT04529824
- Testing
- Dexcom G6 Continuous Glucose Monitor (CGM) System
- Where
- United States
- Volunteers
- 207 people, healthy volunteers welcome
- Sponsor
- DexCom, Inc.
Diabetes Mellitus
FreeStyle Libre Continuous Glucose Monitoring System Accuracy Study
The purpose of this study is to characterize the Freestyle Libre Glucose Monitoring System in pediatric and adult subjects with respect to YSI reference venous plasma sample measurements.
- Trial name
- NCT04464772
- Testing
- FreeStyle Libre 3
- Where
- 4 sites in United States
- Volunteers
- 85 people
- Sponsor
- Abbott Diabetes Care
Diabetes
New Generation Enlite Accuracy Study
The trial will investigate the accuracy and performance of a new sensor for continuous glucose monitoring (CGM), the (new generation) Enlite, CE-marked in 2013, in conjunction with the new Medtronic 640G system components.
- Trial name
- NCT02423798
- Testing
- Glucose sensor (Enlite)
- Volunteers
- 24 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes Mellitus, Diabetes Mellitus, Type 1
Enhance Study: Evaluation of Accuracy and Safety of the Eversense CGM System With Enhanced Features
A Prospective, Multicenter Evaluation of Accuracy and Safety of the Eversense CGM System with Enhanced Features. The purpose of this clinical investigation is to evaluate the accuracy of the Eversense 524 Continuous Glucose…
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT05131139
- Testing
- Continuous Glucose Monitoring System
- Where
- 4 sites in United States
- Volunteers
- 350 people
- Sponsor
- Senseonics, Inc.
Diabetes Mellitus Type 2
Vildagliptin vs Sitagliptin add-on to Insulin - Impact on Glycemic Profile and Correlation of Hypoglycemic Episodes and Heart Function
Vildagliptin and Sitagliptin both belong to the class of DPP-4 inhibitors, but differ in their pharmacokinetic profile as well as in their approved application (Vildagliptin, 2x 50 mg daily, Sitagliptin, 1x 100 mg daily).
- Trial name
- CGM-VISIT (NCT01686932)
- Testing
- Vildagliptin, Sitagliptin
- Where
- 11 sites in Germany
- Volunteers
- 51 people
- Sponsor
- Novartis Pharmaceuticals
Healthy, Impaired Glucose Tolerance
Effects of an Intermittent Fasting and Dietary Supplement Regimen on Glycemic Variability
The purpose of this study is to determine the short-term effect of a nutritional program consisting of a yerba mate supplement, fiber supplement, and intermittent fasting on glycemic variability in men and women with risk factors…
- Trial name
- NCT05493553
- Testing
- Dietary supplement regimen, Dietary supplement and intermittent fasting regimen
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Unicity International, Inc.
Diabetes Mellitus, Type 1 | Diabetes Mellitus, Type 2
Accuracy and Safety of Anytime 5Pro and Anytime 4Pro CGM Systems in Adults With Diabetes
This post-market clinical follow-up (PMCF) investigation evaluates the accuracy and safety of two CE-marked continuous glucose monitoring (CGM) systems, the Anytime 5Pro and the Anytime 4Pro, in adults with type 1 or type 2…
- Trial name
- NCT07645313
- Testing
- Reference venous blood sampling (YSI 2500)
- Volunteers
- 70 people
- Sponsor
- Yuwell Group
Healthy, Prediabetes
Effect of Visualization of Functional Milk Efficacy on Perceived Benefits
This study aims to demonstrate the effect of visualizing the effect of consuming a functional milk on postprandial glucose response on perceived benefits compared to absence of visualization.
- Conditions
- Healthy, Prediabetes, Asian, Adult
- Trial name
- NCT06864364
- Testing
- CGM feedback visualization, milk supplemented with mulberry leaves extract, blinded CGM feedback visualization
- Where
- China
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
type1diabetes, CGM
Evaluation of the Accuracy and Safety of a Continuous Glucose Monitoring System
The study is to evaluate the accuracy and safety of a real-time CGM system among adult patients with type 1 diabetes with respect to reference venous plasma sample measurements.
- Conditions
- type1diabetes, CGM, T1D
- Trial name
- NCT07745244
- Testing
- GS3 CGM
- Where
- China
- Volunteers
- 36 people
- Sponsor
- SiBionics, Co, Ltd
Type 1 Diabetes, Type 2 Diabetes
Feasibility Trial of the Bios Device for Continuous Glucose Monitoring
The study is an open-label, prospective, within-subject comparison of the Bios device readings versus venous blood sample glucose readings, glucose readings from a Dexcom CGM and an SMBG device in subjects previously diagnosed…
- Trial name
- NCT04226846
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- GraphWear Technologies Inc.
Diabetes Mellitus
Prolongation of GLP-1 Adherence When Using Continuous Glucose Monitoring
This study is to see if the FreeStyle Libre 3 Continuous Glucose Monitoring System (FSL3) will help prolong the length of time people with diabetes maintain adherence to glucagon-like peptide 1 (GLP-1/GIP) agonists.
- Trial name
- NCT06668935
- Testing
- To utilize the FreeStyle Libre 3 Continuous Glucose Monitoring System (FSL3) to help prolong the length of time people with diabetes maintain adherence to GLP-1 and dual GIP/GLP-1 agonists
- Where
- 8 sites in United States
- Volunteers
- 800 people
- Sponsor
- Abbott Diabetes Care
Diabetes (DM)
A Study to Investigate a Transdermal Continuous Glucose Monitoring System in Diabetic Patients for a Period of 28 Days
Single-centre, open label (unblinded). A maximum of 48 patients will be enrolled in 4 Cohorts of 10 patients and 2 potential replacements each. Diabetic patients (type 1 and 2).
- Trial name
- FiberSense (NCT06868043)
- Testing
- FiberSense System
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- EyeSense GmbH
Diabetes, Diabetes Mellitus
Biolinq Safety and Effectiveness Trial
The primary objective of the study is to evaluate the safety and effectiveness of the Biolinq MicroArray Intradermal Continuous Glucose Biowearable System, which is intended to be worn for up to five (5) days (up to 120 hours) in…
- Trial name
- NCT06229743
- Testing
- Biolinq System
- Where
- 6 sites in United States
- Volunteers
- 247 people
- Sponsor
- Biolinq Inc.
Type 1 Diabetes
Safety Evaluation of MiniMed™ 780G System With DS5 CGM in Children
The purpose of this study is to evaluate the safety of the MiniMed 780G insulin pump used in combination with the DS5 CGM in type 1 pediatric subjects (2-6 years of age) in a home setting.
- Trial name
- SUCCEED2 (NCT06604871)
- Testing
- Insulin Pump with Continuous Glucose Monitoring
- Where
- 8 sites in United States
- Volunteers
- 56 people
- Sponsor
- Medtronic MiniMed, Inc.